PDGFRA and gastrointestinal stromal tumor: In this group patients with GISTs harboring a PDGFRA D842V mutation are therefore over-represented in the primary resistant GIST group as well as wt-GIST and KIT exon 9-mutated GISTs initially treated with only 400 mg of imatinib [16,51].